Case report

Everolimus and papillomavirus lesions in female renal transplant recipient: A case report

Simundic T. a,d,⁎, Zibar L. b, Sego K. c

a Department of Nephrology, University Hospital Center Osijek, Hutlerova 4, 31000 Osijek, Croatia
b Department of Nephrology, University Hospital Center Osijek, Faculty of Medicine, University of Osijek, Hutlerova 4, 31000 Osijek, Croatia
c Department of Cardiovascular Surgery, University Hospital Center Osijek, Faculty of Medicine, University of Osijek, Hutlerova 4, 31000 Osijek, Croatia
d Faculty of Medicine, University of Osijek, Hutlerova 4, 31000 Osijek, Croatia

A R T I C L E   I N F O

Keywords:
Human papillomavirus
Everolimus
Genital condyloma
Renal transplantation
Cervical intraepithelial neoplasia

A B S T R A C T

We describe the case of a transplanted patient with high-risk HPV infection that manifested as multiple genital condylomas and abnormal Papanicolaou (Pap) smear. Her immunosuppressants were corticosteroids, cyclosporine, and azathioprine. Since gynecologic treatments to eradicate condylomas were completely unsuccessful, cyclosporine was replaced by everolimus. Soon after, condylomas disappeared, HPV status became negative, and Pap smear returned to normal and has remained normal since.

1. Introduction

Human papillomavirus (HPV) infection affects hundreds of millions of people worldwide and is associated with benign and malignant neoplasms of the anogenital region in men and women. HPV is a DNA virus, classified into high-risk and low-risk types based on the virus’s tendency to cause cancer. Besides cancer, low-risk and high-risk HPV (hrHPV) can cause anogenital warts (condyloma acuminata). Clearance of HPV infection depends on adequate immunity, and it happens in more than 90% of cases of immunocompetent individuals (Plummer et al., 2007). Renal transplant recipients (RTRs) due to lifelong immunosuppression (IS) therapy are at high risk of developing persistent infection, treatment-refractory anogenital condylomas, and HPV-related cancer (Reusser et al., 2015). Among female RTRs, cervical cancer is one of the biggest concerns since it is one of the most common types of cancer in women worldwide. In the majority of cases, it is caused by hrHPV (Munoz et al., 2006). It has even been shown that spontaneous regression rate of HPV-related diseases in female RTRs, if left untreated, was 0% (Tanaka et al., 2016). If actively treated, HPV-related diseases still persisted in 43% of cases (Tanaka et al., 2016). In contrast, the condition of the majority of immunocompetent patients regressed spontaneously (Tanaka et al., 2016).

There is evidence that most patients in the pretransplant period with normal cervical cytology change to abnormal cytology in the post-transplant period due to either reactivation of a latent or new HPV infection (Wang et al., 2012). Also, progression in abnormal cervical cytology happens significantly faster in transplant patients than in the general population (Tanaka et al., 2016).

IS therapy decreases the ability to eradicate new HPV infection and permits HPV replication in latently infected cells. The aim of IS therapy is to prevent graft rejection, while altering as little as possible the immunity unrelated to the graft, such as viral reactivation. Some of the IS protocols include mammalian target of rapamycin inhibitors (mTORi), such as everolimus.

2. Case presentation

A 16-year-old girl came to Croatia in 1992 as a refugee due to war. According to the available medical chart and her knowledge, she had no serious illnesses in childhood. During 1992, she began taking antihypertensive therapy. The same year, she underwent an urgent abdominal surgery with resection of 80 cm of ileum due to gangrenous changes of the intestine. Right after the surgery she became oliguric and underwent dialysis for the first time. Abdominal ultrasound revealed very small kidneys with chronic alterations. For that reason, kidney biopsy had never been done. Soon after, she had arteriovenous fistula constructed and had begun hemodialysis sessions three times a week.

In December 1998, she underwent cadaveric kidney transplant, and in 1999 she underwent bilateral native kidney nephrectomy due to unregulated hypertension. During the first two years after transplant she had three episodes of acute graft rejection and was successfully treated with boluses of corticosteroids. Afterward, kidney graft function was stable with creatinine 140 to 150 μmol/L (1.6 mg/dL). Her regular IS therapy were corticosteroids, cyclosporine, azathioprine, and...
anthypertensive therapy, with well-regulated blood pressure.

Until 2008, the patient did not experience any medical crisis. But in 2008, a Papanicolaou (PAP) test for the first time showed cervical intraepithelial neoplasia stage I (CIN I) and hrHPV infection. Ever since, she has had regular gynecologic checkups every 6 months. Colposcopy and Schillers iodine test were positive several times, along with CIN I and hrHPV. Since 2010, she had begun having problems with multiple genital condylomas (condylomata acuminate vaginae et vulvae). Therefore, over the next 2 years she underwent several gynecologic treatments: electrocauterization, electroexcision, and podophyllin therapy. Since that therapy proved completely unsuccessful, cyclosporine was replaced by everolimus in May 2012. Since 2013, she had no more genital condylomas, although PAP smear was still CIN I and hrHPV positive. In the meantime, she became HPV negative, with completely normal PAP test. Gynecologic findings have been within normal range for 3 years now. Graft function is maintained, with slowly “creeping” creatinine, at current levels around 280–300 µmol/L (3.16–3.39 mg/dL). Currently, her regular therapy consists of everolimus 2 × 1 mg, azathioprine 50 mg, prednisone 5 mg every other day, antihypertensive therapy (perindopril/amlopidine 4/5 mg), folic acid, and calcitriol. Plasma concentration of everolimus has been maintained at a range 1–2 µg/L, as she was intended to reach a lower level of overall IS due to her chronic infection and premalignant history.

3. Discussion

Besides IS characteristics, mTORi also have positive immunomodulatory effects. Compared with other IS drugs after renal transplantation, mTORi have been proven to cause a lower rate of de novo malignancy, less nephrotoxicity, and a lower rate of cytomegalo-virus disease (Nashan et al., 2012; Brennan et al., 2011). They are also a choice for BK virus nephropathy (Polanco et al., 2015). This class of ISs also leads to an increase in number and quality of antigen-specific CD8 + memory T-cells (Araki et al., 2009). They stimulate innate immunity (Saemann et al., 2009) and reverse some of the negative effects of glucocorticosteroids on innate immunity (Weichhart et al., 2011).

Everolimus, as an mTORi, is currently recommended for various conditions, including preventing organ rejection after renal transplant. It is also known for its antiviral and anticancer effects. It is well known that mTOR signaling pathway is activated in both HPV-positive and HPV-negative cervical carcinoma (Molinolo et al., 2012). It also has been shown that mTORi activation occurs in at least 60% of the HPV-caused cancers (Feng et al., 2009). At the same time, female solid organ transplant recipients with HPV infection are at a 20–60% of the HPV-caused cancers (Feng et al., 2009). At the same time, female solid organ transplant recipients with HPV infection are at a 20–60% of the HPV-caused cancers (Feng et al., 2009). At the same time, female solid organ transplant recipients with HPV infection are at a 20–60% of the HPV-caused cancers (Feng et al., 2009). At the same time, female solid organ transplant recipients with HPV infection are at a 20–60% of the HPV-caused cancers (Feng et al., 2009). At the same time, female solid organ transplant recipients with HPV infection are at a 20–60% of the HPV-caused cancers (Feng et al., 2009). It also has been shown that mTORi activation occurs in at least 60% of the HPV-caused cancers (Feng et al., 2009). At the same time, female solid organ transplant recipients with HPV infection are at a 20–60% of the HPV-caused cancers (Feng et al., 2009). At the same time, female solid organ transplant recipients with HPV infection are at a 20–60% of the HPV-caused cancers (Feng et al., 2009). It also has been shown that mTORi activation occurs in at least 60% of the HPV-caused cancers (Feng et al., 2009). At the same time, female solid organ transplant recipients with HPV infection are at a 20–60% of the HPV-caused cancers (Feng et al., 2009). At the same time, female solid organ transplant recipients with HPV infection are at a 20–60% of the HPV-caused cancers (Feng et al., 2009). At the same time, female solid organ transplant recipients with HPV infection are at a 20–60% of the HPV-caused cancers (Feng et al., 2009).

Conflit of interest statement

Authors have no conflict of interest to declare.

References

Araki, K., Turner, A.P., Shaffer, V.O., Gangappa, S., Keller, S.A., Bachmann, M.F., et al., 2009. mTOR regulates memory CD8 T-cell differentiation. Nature 460 (7251), 108–112.

Avery, R.K., Michaels, M., 2008. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am. J. Transplant. 8 (1), 9–14.

Brennan, D.C., Legendre, C., Patel, D., Mange, K., Wiland, A., McCague, K., et al., 2011. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplant recipients: pooled analysis of three clinical trials. Am. J. Transplant. 11 (11), 2453–2462.

Feng, W., Duan, X., Liu, J., Xiao, J., Brown, R.E., 2009. Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int. J. Clin. Exp. Pathol. 2 (3), 249–260.

Hinten, F., Meewis, K.A., van Rossum, M.M., de Hulst, J.A., 2012. HPV-related (pre) malignancies of the female anogenital tract in renal transplant recipients. Curr. Rev. Oncol. Hematol. 84 (2), 161–180.

Molinolo, A.A., Marsh, C., El Dinah, M., Gangane, N., Jenkinson, K., Hewitt, S., et al., 2012. mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. Clin. Cancer Res. 18 (9), 2558–2568.

Munoz, N., Castellsague, X., de Gonzalez, A.B., Gissmann, L., 2006. Chapter 1: HPV in the etiology of human cancer. Vaccine 24 (Suppl. 3), S3/1–10.

Nashan, B., Gaston, R., Emery, V., Saemann, M.D., Mueller, N.J., Cousi, L., et al., 2012. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 93 (11), 1075–1085.

Plummer, M., Schiffman, M., Castle, P.E., Maucoert-Bouchl, D., Wheeler, C.M., Group, A., 2007. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J. Infect. Dis. 195 (11), 1582–1589.

Polanco, N., Gonzalez Monte, E., Folgueira, M.D., Morales, E., Gutierrez Martinez, E., Bensos, I., et al., 2015. Everolimus-based immunosuppression therapy for BK virus nephropathy. Transplant. Proc. 47 (1), 57–61.

Reusser, N.M., Downing, C., Guidry, J., Tying, S.K., 2015. HPV Carcinomas in Immunocompromised Patients. J. Clin. Med. 4 (3), 260–281.

Saemann, M.D., Haidinger, M., Hecking, M., Herl, W.H., Weichhart, T., 2009. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am. J. Transplant. 9 (12), 2655–2661.

Tanaka, Y., Ueda, Y., Kukuda, M., Kubota, S., Matsuzaki, S., Nakagawa, S., et al., 2016. Clinical outcomes of abnormal cervical cytology and human papillomavirus-related lesions in patients with organ transplantation: 11-year experience at a single institution. Int. J. Clin. Oncol. 21 (4), 730–734.

Wang, Y., Brinch, L., Jebsen, P., Tanbo, T., Kirschner, R., et al., 2012. A clinical study of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 18 (5), 747–753.

Weichhart, T., Haidinger, M., Kotheling, K., Kopecky, C., Poglitosh, M., Lansonig, C., et al., 2011. Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells. Blood 117 (16), 4273–4283.